Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

Abstract excerpt

Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histone Deacetylase Inhibitors Research
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors